Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsPreethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5APreethi Krishnan, Jill Beyer, Neeta Mistry, et al.Antimicrobial Agents and Chemotherapy|December 9, 2015
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and OmbitasvirPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.Journal of Extracellular Vesicles|December 11, 2019
Extracellular vesicles containing oncogenic mutant β-catenin activate Wnt signalling pathway in the recipient cellsHina Kalra, Lahiru Gangoda, Pamali Fonseka, et al.Antimicrobial Agents and Chemotherapy|November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.Plos One|January 5, 2024
The impact of online education during the Covid-19 pandemic on the professional identity formation of medical students: A systematic scoping reviewJonathan Zhen Liang, Donovan Kai Wei Ng, Vijayprasanth Raveendran, et al.Journal of Medical Virology|August 27, 2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavirGretja Schnell, Rakesh Tripathi, Preethi Krishnan, et al.Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Tami Pilot-Matias, Rakesh Tripathi, Daniel Cohen, et al.Pageof 5